Table of ContentsView AllTable of ContentsDrug DifferencesHow Do Wegovy and Ozempic Work?Potential Side EffectsDrug Interactions
Table of ContentsView All
View All
Table of Contents
Drug Differences
How Do Wegovy and Ozempic Work?
Potential Side Effects
Drug Interactions
For people looking to treat and manage theirtype 2 diabetes, or for those looking to accelerate weight loss that is associated with type 2 diabetes,hypertension(high blood pressure), orhigh cholesterol, the use of prescription medication is a viable treatment strategy.
For this purpose, healthcare professionals may recommend Wegovy (semaglutide) or Ozempic (semaglutide). Both contain the same active ingredient: a glucagon-like peptide-1 (GLP-1) receptor agonist. However, the two brand-name products have different uses.
While you may have heard of these drugs before or know someone prescribed Wegovy or Ozempic, you likely have questions or concerns over which drug best suits your or a loved one’s needs.
To address these questions, this article will highlight the similarities and differences between Wegovy and Ozempic, including their approved indications (conditions for which a drug can be used) and off-label uses.
Getty Images / Douglas Cliff.
Wegovy vs. Ozempic: How Are They Different?
Ozempic and Wegovy have key differences and several similarities. They differ mainly in their FDA-approved indications and typical dosages.
Uses
Ozempic is FDA-approved for the following uses:
Wegovy is approved for chronic (long-term) weight management in certain people, including:
Additionally, Wegovy is FDA-approved to reduce the risk of serious heart problems in adults with obesity or who are overweight and for weight loss.
Unlike Wegovy, Ozempic does not have any specific BMI requirements. Ozempic is not approved for use in children.
BMI is a dated, flawed measure. It does not take into account factors such asbody composition, ethnicity, sex, race, and age. Even though it is a biased measure, BMI is still widely used in the medical community because it’s an inexpensive and quick way to analyze a person’s potential health status and outcomes.
Ways to Save on Mounjaro and Ozempic
Administration and Dosage
Both Wegovy and Ozempic are once-weeklysubcutaneous injections(injections given under the skin), but Wegovy has a higher maximum dosage than Ozempic.
You or a caregiver will inject it under the skin of your abdomen, thigh, or upper arm. Wegovy and Ozempic can be given any time on the same day of the week, such as every Sunday.
Wegovy’s starting dose in adults is 0.25 milligrams (mg) once weekly for four weeks. Your healthcare provider will increase your dose every four weeks until you reach the target dose of 2.4 milligrams once weekly.
Wegovy’s starting dose in children is 0.25 milligrams once weekly for four weeks. Your child’s healthcare provider will increase the dose every four weeks until the target dose of 1.7 or 2.4 milligrams once weekly is reached.
Ozempic’s starting doseis 0.25 milligrams once weekly for four weeks. Then your healthcare provider will raise your dosage to 0.5 milligrams once weekly.
If yourblood sugarlevels are still too high at the 0.5 milligrams dose, your healthcare provider may increase your dose to 1 or 2 milligrams once weekly. The maximum amount of Ozempic is 2 milligrams.
How to Store Wegovy and OzempicStore Wegovy in the refrigerator until you are ready to use it. Once you remove it from the fridge, Wegovy stays good at room temperature for 28 days (four weeks).Ozempic is also kept in the refrigerator. Once you remove it from the fridge and it reaches room temperature, any unused drugexpiresafter 56 days (eight weeks).
How to Store Wegovy and Ozempic
Store Wegovy in the refrigerator until you are ready to use it. Once you remove it from the fridge, Wegovy stays good at room temperature for 28 days (four weeks).Ozempic is also kept in the refrigerator. Once you remove it from the fridge and it reaches room temperature, any unused drugexpiresafter 56 days (eight weeks).
Store Wegovy in the refrigerator until you are ready to use it. Once you remove it from the fridge, Wegovy stays good at room temperature for 28 days (four weeks).
Ozempic is also kept in the refrigerator. Once you remove it from the fridge and it reaches room temperature, any unused drugexpiresafter 56 days (eight weeks).
Both Wegovy and Ozempic are GLP-1 agonists containing semaglutide.
Which Is More Effective?
Both Wegovy and Ozempic have been evaluated extensively in separate clinical trials, particularly related to weight loss and type 2 diabetes.
Weight Loss:
Type 2 Diabetes:
Side Effects and Safety
Since Wegovy and Ozempic contain the same active ingredient, they can cause the sameside effectsand should not be used together.
It should be noted that Wegovy and Ozempic carry a boxed warning—the FDA’s most strict warning regarding serious side effects—for the severe risk ofthyroid C-cell tumors.
In studies, both medications caused thyroid C-cell tumors in rats and mice. However, it is unknown whether semaglutide causes thyroid C-cell tumors, includingmedullary thyroid carcinoma(MTC), in humans.
Common Side Effects
The most common side effect reported for Wegovy and Ozempic is gastrointestinal (GI) upset. This side effect may ease as your body gets used to the medication.
Common side effects of both Wegovy and Ozempic include:
What is Ozempic Face?“Ozempic face” is a slang term that describes a possible side effect ofsagging facial skindue to weight loss when first taking Ozempic. This side effect can also occur with Wegovy and other GLP-1 agonists.Rapid weight loss can sometimes cause thefacial skinto stretch out and lose elasticity, appearing as sagging or loose.
What is Ozempic Face?
“Ozempic face” is a slang term that describes a possible side effect ofsagging facial skindue to weight loss when first taking Ozempic. This side effect can also occur with Wegovy and other GLP-1 agonists.Rapid weight loss can sometimes cause thefacial skinto stretch out and lose elasticity, appearing as sagging or loose.
“Ozempic face” is a slang term that describes a possible side effect ofsagging facial skindue to weight loss when first taking Ozempic. This side effect can also occur with Wegovy and other GLP-1 agonists.
Rapid weight loss can sometimes cause thefacial skinto stretch out and lose elasticity, appearing as sagging or loose.
Severe Side Effects
Less common but potentially severe side effects of Wegovy and Ozempic may include:
Wegovy and Ozempic are not recommended for individuals with a personal or family history of MTC ormultiple endocrine neoplasia syndrome type 2.
In addition, it isn’t known if Wegovy and Ozempic are safe to use in people with past or activepancreatitis(inflammation of the pancreas).
8 FDA-Approved Drugs for Weight Management
What Medications Interact With Wegovy or Ozempic?
As with most medications, both Wegovy and Ozempic carry the risk of adverse interactions if taken along with other drugs, including the following:
Because of these interactions, talk with your healthcare provider about all medicines you currently take before starting Wegovy or Ozempic.
Summary
Wegovy and Ozempic are similar medications. The FDA approves these drugs for different purposes, but both may causeweight loss.
Ozempic improves outcomes in adults withtype 2 diabetes, while Wegovy promotesweight lossin adults and adolescents who meet specific criteria.
Wegovy and Ozempic are meant to be used with exercise and diet changes.
The side effects are similar, with stomach upset being the most common.Talk to a healthcare provider if you think trying Wegovy or Ozempic is right for you.
14 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.National Heart, Lung, and Blood Institute.Overweight and obesity: treatment.Food and Drug Administration.Ozempic (semaglutide) prescribing information.Food and Drug Administration.Wegovy (semaglutide) prescribing information.Prescribers' Digital Reference.Semaglutide - drug summary.MedlinePlus.Semaglutide injection.Tran KL, Park YI, Pandya S, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10(4):178-188.Wadden TA, Bailey TS, Billings LK, et al.Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.J Am Med Assoc. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831Davies M, Færch L, Jeppesen OK, et al.Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial.The Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0Food and Drug Administration.Drug trial snapshot: Ozempic.Centers for Disease Control and Prevention.Testing for diabetes and prediabetes: A1C.Tay JQ.Ozempic face: A new challenge for facial plastic surgeons [published online ahead of print, 2023 Apr 20].J Plast Reconstr Aesthet Surg. 2023;81:97-98. doi:10.1016/j.bjps.2023.04.057DailyMed.Label: Victoza- liraglutide injection.DaiyMed.Label: Rybelsus- oral semaglutide tablet.Almandoz JP, Lingvay I, Morales J, Campos C.Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance.Clin Diabetes. 2020;38(4):390-402. doi:10.2337/cd19-0100
14 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.National Heart, Lung, and Blood Institute.Overweight and obesity: treatment.Food and Drug Administration.Ozempic (semaglutide) prescribing information.Food and Drug Administration.Wegovy (semaglutide) prescribing information.Prescribers' Digital Reference.Semaglutide - drug summary.MedlinePlus.Semaglutide injection.Tran KL, Park YI, Pandya S, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10(4):178-188.Wadden TA, Bailey TS, Billings LK, et al.Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.J Am Med Assoc. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831Davies M, Færch L, Jeppesen OK, et al.Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial.The Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0Food and Drug Administration.Drug trial snapshot: Ozempic.Centers for Disease Control and Prevention.Testing for diabetes and prediabetes: A1C.Tay JQ.Ozempic face: A new challenge for facial plastic surgeons [published online ahead of print, 2023 Apr 20].J Plast Reconstr Aesthet Surg. 2023;81:97-98. doi:10.1016/j.bjps.2023.04.057DailyMed.Label: Victoza- liraglutide injection.DaiyMed.Label: Rybelsus- oral semaglutide tablet.Almandoz JP, Lingvay I, Morales J, Campos C.Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance.Clin Diabetes. 2020;38(4):390-402. doi:10.2337/cd19-0100
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
National Heart, Lung, and Blood Institute.Overweight and obesity: treatment.Food and Drug Administration.Ozempic (semaglutide) prescribing information.Food and Drug Administration.Wegovy (semaglutide) prescribing information.Prescribers' Digital Reference.Semaglutide - drug summary.MedlinePlus.Semaglutide injection.Tran KL, Park YI, Pandya S, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10(4):178-188.Wadden TA, Bailey TS, Billings LK, et al.Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.J Am Med Assoc. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831Davies M, Færch L, Jeppesen OK, et al.Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial.The Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0Food and Drug Administration.Drug trial snapshot: Ozempic.Centers for Disease Control and Prevention.Testing for diabetes and prediabetes: A1C.Tay JQ.Ozempic face: A new challenge for facial plastic surgeons [published online ahead of print, 2023 Apr 20].J Plast Reconstr Aesthet Surg. 2023;81:97-98. doi:10.1016/j.bjps.2023.04.057DailyMed.Label: Victoza- liraglutide injection.DaiyMed.Label: Rybelsus- oral semaglutide tablet.Almandoz JP, Lingvay I, Morales J, Campos C.Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance.Clin Diabetes. 2020;38(4):390-402. doi:10.2337/cd19-0100
National Heart, Lung, and Blood Institute.Overweight and obesity: treatment.
Food and Drug Administration.Ozempic (semaglutide) prescribing information.
Food and Drug Administration.Wegovy (semaglutide) prescribing information.
Prescribers' Digital Reference.Semaglutide - drug summary.
MedlinePlus.Semaglutide injection.
Tran KL, Park YI, Pandya S, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10(4):178-188.
Wadden TA, Bailey TS, Billings LK, et al.Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.J Am Med Assoc. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831
Davies M, Færch L, Jeppesen OK, et al.Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial.The Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0
Food and Drug Administration.Drug trial snapshot: Ozempic.
Centers for Disease Control and Prevention.Testing for diabetes and prediabetes: A1C.
Tay JQ.Ozempic face: A new challenge for facial plastic surgeons [published online ahead of print, 2023 Apr 20].J Plast Reconstr Aesthet Surg. 2023;81:97-98. doi:10.1016/j.bjps.2023.04.057
DailyMed.Label: Victoza- liraglutide injection.
DaiyMed.Label: Rybelsus- oral semaglutide tablet.
Almandoz JP, Lingvay I, Morales J, Campos C.Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance.Clin Diabetes. 2020;38(4):390-402. doi:10.2337/cd19-0100
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.Cookies SettingsAccept All Cookies
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies SettingsAccept All Cookies
